抗结核药物作用新靶点及其研究进展  

Research progress of new targets for antituberculosis agents

作　　者：陈浩 武楠楠 胡文辉 杨忠金 CHEN Hao;WU Nan-nan;HU Wen-hui;YANG Zhong-jin(Research Institute of Snake Venom,School of Pharmaceutical Sciences,Guangzhou Medical University,Guangzhou,1436,China)

机构地区：[1]广州医科大学药学院蛇毒与生物毒素研究所,511436

出　　处：《中国防痨杂志》2020年第3期286-292,共7页Chinese Journal of Antituberculosis

基　　金：广州医科大学学生科技创新项目(2018A003)。

摘　　要：结核病是威胁我国乃至全世界的健康问题。由于细菌变异、治疗方案不合理和药物滥用等原因导致细菌耐药情况越来越严重,耐药结核病已经威胁到了全人类的健康安全。近10年来针对结核分枝杆菌各种新靶点的抗结核新药已经陆续进入临床试验,作者对抗结核分枝杆菌研究中细胞壁合成、蛋白质合成和能量代谢机制的新靶点进行梳理和分析,并且对一些相关的新型化合物进行简要介绍,以期为抗结核药物的研发提供参考。Tuberculosis remains a health problem that threatens our country and the world.Bacterial resistance is becoming more and more serious due to bacterial mutations,irrational treatment options,and drug abuse,and drug-resistant tuberculosis has threatened the health and safety of all human beings.In the past decade,many new anti-tuberculosis drugs targeting various new targets of Mycobacterium tuberculosis have been gradually started clinical trials.This review analyzes the new targets for cell wall synthesis,protein synthesis and energy metabolism in the study of anti-Mycobacterium tuberculosis and briefly introduce some related new compounds,in order to provide reference for the development of anti-tuberculosis drugs.

关 键 词：抗结核药 新靶点 新型化合物 研究进展 

分 类 号：R978.3[医药卫生—药品]